Physician profile
Raymond Rojas
NPI 1609844273
$827.03
in general payments reported to CMS, 2019-2025
15 companies · $21.16 in 2025
The $21.16 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $23.06 · 2022: $187 · 2023: $366 · 2024: $118 · 2025: $21.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $487 · Education: $17.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $486.81 |
| Education | $17.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $130.85 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2022 | |
| Dompe US, INC. | $110.29 | 2023 | Oxervate |
| Allergan, INC. | $99.99 | 2019 | |
| Pfizer INC. | $73.01 | 2023-2024 | |
| Exact Sciences Corporation | $48.47 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $45.15 | 2023-2024 | Arexvy, Shingrix |
| Idorsia Pharmaceuticals US INC | $40.67 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $26.01 | 2024 | |
| Merck Sharp & Dohme LLC | $25.17 | 2023 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $23.98 | 2023 | Eliquis |
| Impel Pharmaceuticals INC. | $23.30 | 2022 | |
| Amarin Pharma, INC. | $23.06 | 2020 | |
| Novo Nordisk INC | $17.74 | 2023 | Rybelsus |
| Amgen INC. | $14.34 | 2023 | Evenity, Prolia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Rojas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.